Genmab A/S General and Administrative Expenses 2011-2026 | GMAB

General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.

What these expenses include

Salaries of administrative staff (executives, HR, accountants, legal personnel)
Office rent and utilities
Office equipment and IT infrastructure
Professional services (auditors, lawyers, consultants)
Insurance
General administrative travel and representation expenses

What the metric indicates

Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure
Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit
Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry
Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines

Annual General and Administrative Expenses Genmab A/S

2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	661 M	342 M	214 M	147 M	102 M	91.2 M	79.5 M	66.7 M	64.6 M	67.9 M

All numbers in DKK currency

Indicator range from annual reports

Maximum	Minimum	Average
661 M	64.6 M	184 M

Quarterly General and Administrative Expenses Genmab A/S

2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	-	-	264 M	-	-	-	179 M	-	-	-	73 M	-	-	-	55.7 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in DKK currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
264 M	55.7 M	143 M

General and Administrative Expenses of other stocks in the Biotechnology industry

Issuer	General and Administrative Expenses	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	78.3 M	-	2.43 %	$ 254 M	Germany
Aligos Therapeutics ALGS	20.7 M	$ 8.7	8.82 %	$ 86 M	USA
Alterity Therapeutics Limited ATHE	5.51 M	$ 3.63	-2.42 %	$ 8.73 B	Australia
I-Mab IMAB	900 M	-	-	$ 866 M	China
AlloVir ALVR	11 M	-	4.14 %	$ 49.1 M	USA
Applied Molecular Transport AMTI	37.4 M	-	-	$ 10.1 M	USA
Alexion Pharmaceuticals, Inc. ALXN	1.4 B	-	-	$ 40.3 B	USA
Genfit SA GNFT	16.2 M	-	2.54 %	$ 160 B	France
Biophytis SA BPTS	7.15 M	-	-13.47 %	$ 169 M	France
Anavex Life Sciences Corp. AVXL	13.8 M	$ 3.06	3.73 %	$ 261 M	USA
Applied Therapeutics APLT	20.6 M	-	-	$ 8.42 M	USA
EyeGate Pharmaceuticals, Inc. EYEG	4.66 M	-	-1.52 %	$ 24.7 M	USA
Midatech Pharma plc MTP	4.95 M	-	-18.52 %	$ 27.3 M	Britain
BioNTech SE BNTX	286 M	$ 97.5	2.09 %	$ 27.2 B	Germany
Amphastar Pharmaceuticals AMPH	85.9 M	$ 20.5	0.64 %	$ 958 M	USA
Acorda Therapeutics ACOR	89.7 M	-	-24.86 %	$ 820 K	USA
Институт стволовых клеток человека ISKJ	25.8 M	-	-	-	Russia
Adverum Biotechnologies ADVM	63.1 M	-	-	$ 86.2 M	USA
Advaxis ADXS	12.2 M	-	-9.65 %	$ 45.9 M	USA
Aeterna Zentaris AEZS	5.92 M	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	11 M	-	-10.17 %	$ 12.2 K	USA
Aeglea BioTherapeutics AGLE	47.9 M	-	-	$ 1.01 B	USA
Akebia Therapeutics AKBA	107 M	$ 1.43	1.79 %	$ 368 M	USA
Applied Genetic Technologies Corporation AGTC	17 M	-	-	$ 26.5 M	USA
Allakos ALLK	45.1 M	-	-	$ 28.6 M	USA
Aptinyx APTX	19.8 M	-	-39.0 %	$ 4.57 M	USA
Can-Fite BioPharma Ltd. CANF	3.66 M	$ 2.96	1.37 %	$ 4.87 M	Israel
Aquestive Therapeutics AQST	79.8 M	$ 4.16	1.84 %	$ 445 M	USA
Aravive ARAV	13 M	-	-13.39 %	$ 1.45 M	USA
Arcutis Biotherapeutics ARQT	275 M	$ 24.22	0.04 %	$ 3.08 B	USA
AIkido Pharma AIKI	23.8 M	-	1.93 %	$ 17.4 M	USA
Celldex Therapeutics CLDX	43.8 M	$ 32.51	0.84 %	$ 2.16 B	USA
Autolus Therapeutics plc AUTL	132 M	$ 1.51	1.01 %	$ 402 M	Britain
Aptose Biosciences APTO	13.4 M	-	-45.71 %	$ 1.2 M	Canada
Cidara Therapeutics CDTX	20.6 M	-	-	$ 1.41 B	USA
AVROBIO AVRO	24 M	-	1083.1 %	$ 745 M	USA
Ayala Pharmaceuticals AYLA	1.53 M	-	-	$ 7.46 M	Israel
Aytu BioScience AYTU	17.4 M	$ 2.61	2.35 %	$ 16.4 M	USA
InflaRx N.V. IFRX	12 M	$ 1.07	7.0 %	$ 152 M	Germany
AstraZeneca PLC AZN	15.2 B	-	-	$ 96.9 B	Britain
Akero Therapeutics AKRO	37.9 M	-	-	$ 3.67 B	USA
CureVac N.V. CVAC	100 M	-	-	$ 867 M	Germany
Brainstorm Cell Therapeutics BCLI	5.78 M	-	-2.5 %	$ 5.88 M	USA
BeiGene, Ltd. BGNE	2.08 B	-	0.49 %	$ 251 B	Cayman-islands
Akouos AKUS	22.2 M	-	0.23 %	$ 488 M	USA
Akari Therapeutics, Plc AKTX	9.28 M	$ 3.99	4.2 %	$ 269 B	Britain
Allena Pharmaceuticals ALNA	12.7 M	-	3.16 %	$ 1.9 M	USA
Baudax Bio BXRX	24.1 M	-	0.59 %	$ 63 K	USA
Cabaletta Bio CABA	29.6 M	$ 3.25	3.83 %	$ 327 M	USA
Alpine Immune Sciences ALPN	18 M	-	-	$ 2.17 B	USA